High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features

BACKGROUND: High-dose interleukin-2 (HD IL-2) is used in the treatment of metastatic renal cell carcinoma (mRCC) and has an overall response rate (ORR) of 12–20% and a complete response rate (CR) of 8% in unselected populations with predominantly clear cell type renal cell carcinoma. Nearly 10–15% o...

Descripción completa

Detalles Bibliográficos
Autores principales: Achkar, Tala, Arjunan, Ananth, Wang, Hong, Saul, Melissa, Davar, Diwakar, Appleman, Leonard J., Friedland, David, Parikh, Rahul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738119/
https://www.ncbi.nlm.nih.gov/pubmed/29261796
http://dx.doi.org/10.1371/journal.pone.0190084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738119/
https://www.ncbi.nlm.nih.gov/pubmed/29261796
http://dx.doi.org/10.1371/journal.pone.0190084

Ejemplares similares